Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional…
Latest news
On the heels of approvals in the US, Europe and Japan, Bayer’s Kerendia for chronic…
Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed…
Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant…
Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline –…
SAE Media Group’s Inaugural Conference…Medical Devices and IVD 202214 – 15 November 2022London, UKhttp://www.medicaldevices-ivd.com Navigating…
One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run…
Pfizer and BioNTech have signed a new $3.2 billion supply contract with the US government…
At the 2022 Drug Information Association (DIA) annual meeting last week, it was inspiring to…
Merck & Co is looking for startup companies applying artificial intelligence, machine-learning and other digital…
The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with…
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer…
Bayer has stepped up the digital capabilities of its radiology business with the launch of…
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has…
Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant…
The NHS App will be updated over the next couple of years to include a…
The prescription medicine market has recovered from the wild swings of the early pandemic with…
A Swiss newspaper has said Novartis’ previously announced restructuring programme could lead to 8,000 axed…
Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which…
SAE Media Group is delighted to announce the 2nd Annual Conference Oligonucleotide Therapeutics & Delivery,…
Sanofi has claimed approval in the EU for Xenpozyme as a treatment for acid sphingomyelinase…
Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series…
Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market…
Digital health company Health2Sync will work with Sanofi on digitising its range of insulin products…
In the first of a three part series, Ben Hargreaves looks at what the odds…
Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin…
NHS patients in England who have been waiting more than two years for surgery will…
An antisense drug in development at GSK has shown further activity against hepatitis B virus…
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart…
The EMA’s human medicines advisory committee has recommended that BioMarin Pharmaceutical’s haemophilia A gene therapy…
The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again,…
Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells…
Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its…
Fujifilm’s Irvine Scientific unit has licensed rights to an artificial intelligence-powered technology developed to improve…
pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about…
Shares in Sarepta came under pressure after the biotech said it had temporarily halted a…
Digital health company Happify has signed a partnership with another biopharma company, joining forces with…
GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up…
Around the world, women are making important contributions to life sciences. In this series, we…
Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the…
Eisai’s digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used…
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral…
Novartis has shouldered its way into the in vivo gene editing category via a deal…
Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong…
Six in 10 respondents to Health Union’s Spondyloarthritis In America 2021 survey said they feel other people…
The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products…
Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of…
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis…
Moderna has said it will open a new R&D and manufacturing facility in the UK…
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer,…